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Summary 
Pathogenic self-reactive antibodies are a significant 
cause of morbidlty and mortality and contribute to both 
cytotoxic and immune complex-trlggered inflamma- 
tory dlsorders, typified by rheumatic diseases, autoim- 
mune hemolytic anemia, and thrombocytopenla. Roles 
have been proposed for Fc receptors, complement, 
and complement receptors in the pathogenesis of 
these disorders, although the contribution of each to 
autoimmune injury is unclear. y chain-deficient mice 
lacking FcyRl and FcyRlll are resistant to the develop 
ment of experimental immune hemolytic anemla in- 
duced by polyclonal rabbit anti-mouse red blood cell 
IgG antibodies. Thls resistance Is primarily a conse- 
quence of ineffective erythrophagocytosls, resulting 
from the lack of FcyRs on mononuclear phagocytes. 
Similarly, y chain-deficient mice are completely resis- 
tant to the development of experimental Immune 
thrombocytopenia induced by mouse anti-platelet an- 
tibodies. These data suggest that Fc receptors play 
an integral role in the pathogenesis of type II hypersen- 
sitlvity and suggest potentlal therapeutic beneflts of 
Fc receptor blockade. 
Introduction 
Pathogenic self-reactive antibody either in the form of solu- 
ble immune complexes or as cellular bound cytotoxic anti- 
body produces autoimmune injury as a consequence of 
activation of the inflammatory response (Ravetch, 1994). 
Type II inflammation, which is characterized by patho- 
genic cytotoxic antibody, contributes to the pathogenesis 
of human autoimmune disease and is specifically causal 
in the development of autoimmune hemolytic anemia 
(AIHA), immune thrombocytopenic purpura (ITP), and 
Goodpasture’s Disease. Three discrete pathways may re- 
sult in the destruction of the antibody-coated target cell 
(Roitt et al., 1993). In one pathway, the direct activation 
of both the early and late components of the complement 
cascade can result in the formation of the membrane at- 
tack complex producing pores in the cell membrane and 
directly lyse the target cell. This mechanism is presumed 
to predominate in causing intravascular hemolysis in 
acute hemolytic transfusion reactions after the administra- 
tion of ABO-incompatible blood (Snyder, 1995). Recruit- 
ment and activation of cellular effecters may be accom- 
plished by the two other pathways: engagement of C3b 
or FcyR receptors, or both. Ligand cross-linking of these 
FoyRs on effector cells in vitro initiates the activation of 
a wide array of effector functions, including phagocytosis, 
antibody-dependent cellular cytotoxicity, and release of 
inflammatory mediators, which ultimatelycanleadtocellu- 
lar destruction and the amplification of the inflammatory 
response (Gallin, 1993). Either or both of these latter two 
mechanisms have been presumed responsible for the ex- 
travascular hemolysis seen in warm AIHA and ITP. 
In the mouse, there are three classesof Fc receptors for 
immunoglobulin G (IgG): the high affinity receptor FqRI, 
capable of binding monomeric IgG, and the two low aff inky 
receptors, FcyRll and FcyRIII, which bind polymeric IgG. 
While FcyRll is a single subunit receptor, both FcyRl and 
FcyRlll are hetero-oligomeric complexes and require an 
additional chain for their assembly and signaling: the ho- 
modimeric y subunit (Ra et al., 1989; Lanier et al., 1989; 
Kurosaki and Ravetch, 1989; Ernst et al., 1993). All three 
classes of Fc receptors are expressed on myeloid lineage 
cells, including macrophages and neutrophils. In contrast, 
FcyRlll is the sole FcR on natural killer cells (reviewed by 
Ravetch, 1994). 
Previous work using FcRy chain-deficient mice that are 
unable to express FcyRl and FcrRlll (Takai et al., 1994) 
revealed an unexpected role for Fc receptor engagement 
in the initiation of IgG immune complex-triggered type 
Ill inflammation, as demonstrated by the absence of an 
Arthus reaction in these mice (Sylvestre and Ravetch, 
1994). In the present study, we provide evidence that Fc 
receptor engagement is pivotal to the development of dis- 
ease in two models of type II hypersensitivity; namely, 
experimental immune thrombocytopenia and hemolytic 
anemia. 
Genetic susceptibility to AIHA has been demonstrated 
in a number of inbred mouse lines and studied most exten- 
sively in NZB mice. Nearly all NZB mice develop AIHA 
by the age of 9 months, highlighted by the serological 
appearance of autoreactive anti-red blood cell antibodies 
(Howie and Helyer, 1988). A number of NZBderived patho 
genie anti-mouse red blood cell (aMRBC) hybridomas 
have been described (Reininger et al., 1990), and two of 
these monoclonal antibodies (MAbs), 34-3C and 31-90, 
have revealed that two disparate pathogenic mechanisms 
are responsible for the anemia observed (Shibata et al., 
1990). 
Autoimmune thrombooytopenia and the appearance of 
autoreactive anti-platelet antibodies occurs in genetically 
susceptible inbred mouse strains (Mizutani et al., 1990). Re- 
cently, a pathogenic IgGl MAb @AS) was derived from BSX 
mice, which induces a rapid transient thrombocytopenia in 
intravenously injected animals (Mizutani et ‘al., 1993). The 
pathogenic mechanism of this experimental immune throm- 
bocytopenia has not yet been described. In this study, we 
examined the development of experimental autoimmune 
thrombocytopenia and hemolytic anemia in FcyRI- and 
Fc-rRllldeficient mice, as well as in osteopetrotic (op/op) 
mice, which have abnormal mononuclear cell development 
as a consequence of the functional loss of CSF-1 (Yoshida 
et al., 1990; WiktorJedrzejczak et al., 1990; Felix et al., 
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Figure 1. Experimental Murine Immune Hemolytic Anemia Induced 
by Rabbit Polyclonal Anti-Mouse Red Blood Cell IgG 
Daily hematocrits of wild-type (+/+, closed circles and squares) and 
homozygous y chain-deficient littermates (-I-. open circles and 
squares). Circles denote uninjected control animals and squares de- 
note animals injected with rabbit anti-mouse RBC IgG. 
1990). We show that FcyR-bearing cells are critical to the 
development of these models of type II autoimmunity, and 
that the hepatic macrophage is of greater importance in im- 
mune hemolytic anemia than in immune thrombocytopenia. 
Reeulte and Discussion 
Experlmental Immune Hemolytic Anemia 
in y-j- Mice 
To determine whether cytotoxic antibodies require FcRs to 
mediate their effects, FcyRI- and FcyRllldeficient mice or 
their wild-type littermates were injected intraperiioneally with 
200 ug of a polyclonal rabbit anti-mouse red blood cell IgG 
fraction. As shown in Figure 1, wild-type littermates became 
profoundly anemic with an average hematocrit of 23.7% on 
day 4 postinjection, whereas knockout mice were relatively 
resistant to the pathogenic effects of this antibody, resulting 
in an average hematocrit of 36.5%. 
We next investigated the mechanisms of the FcRdepen- 
dent and FcR-independent anemia induced by RaMRBC 
IgG. Histopathological examination of the livers and spleens 
of treated animals revealed a greater degree of hepato- 
splenomegaly in wild-type mice injected with RaMRBC, with 
prominent evidence of hepatic erythrophagocytosis (Figure 
2A) and splenic engorgement (Figure 28) as compared 
with their knockout littermates. These data suggest that 
polyclonal RaMRBC IgG is likely to be inducing anemia 
predominately through erythrophagocytosis, mediated 
through FcR engagement. The persistent though dimin- 
ished pathology observed in the knockout animals is likely 
to be the result of FcR-independent processes, such as 
agglutination (Figure 28). Additional evidence for these 
conclusions was obtained by the use of three mouse MAbs 
directed against mouse RBCs, which elicit autoimmune 
anemia through different mechanisms. MAb 34-3C has 
been shown to induce erythrophagocytosis by peritoneal 
macrophages in vitro and by splenic and hepatic mononu- 
clear cells in vivo. The anemia induced by MAb 31-9D 
is mediated instead by red blood cell agglutination and 
subsequent hepatic and splenic mechanical sequestra- 
tion. In contrast, the administration of a polyclonal rabbit 
anti-MRBC sera would be expected to activate both com- 
plement-dependent and independent pathways, resulting 
in both intravascular and extravascular hemolysis (Vitale 
et al., 1967). 
Injection of MAb 34-3C resulted in an average hemato- 
crit in wild-type mice of 23% at day 4 postinjection, while in 
knockout mice hematocrit levels remained at 45% (Figure 
3A) and had no evidence of hepatic erythrophagocytosis 
(see Figure 2A). In contrast, MAb 31-9D resulted in hema- 
tocrits of 25% in both wild-type and knockout mice, while 
4C6 reduced the hematocrits of wild-type and knockout 
animals to 35% (Figures 38,3C). Histopathological exami- 
nation of knockout animals injected with 31-9D revealed 
similar degrees of splenomegaly and microscopic aggluti- 
nation in the sinusoids of the liver and spleen (data not 
shown). Additionally, knockout and wild-type animals 
showed similar rates of recovery with stabilization of hema- 
tocrits at 40%-500/b by day 7. This recovery process was 
accompanied by similar histological evidence of extra- 
medullary hematopoiesis in the liver and spleen and equiv- 
alent levels of reticulocytosis in the peripheral blood (data 
not shown). The role of complement in the residual anemia 
induced in knockout mice by RaMRBC was determined by 
depleting complement C3 with cobra venom factor. Cobra 
venom factor-treated mice were not significantly pro- 
tected from anemia (Figure 3C), indicating that comple- 
ment-mediated pathways do not significantly contribute 
to the residual pathology seen in FcR-deficient animals. 
Thus, despite the fact that complement and complement 
receptors are normal in these mice and can be activated 
by appropriate stimuli (Sylvestre and Ravetch, 1994) and 
incubation of RaMRBC IgG with mouse RBCs and serum, 
in vitro, results in hemolysis, the in vivo role of complement 
in this model of immune hemolytic anemia appears to be 
minimal. 
Experimental Immune Hemolytic Anemia 
In op/op Mice 
The FcrR-expressing cell responsibleforthe experimental 
AIHA we observe is likely to be the splenic macrophage 
and hepatic Kupffer cell. We have found that the adult op/ 
op mouse, which carries a mutation in the CSF-1 gene, is 
less susceptible to the induction of anemia by MAb 34-3C 
(Table 1). These mice have greatly reduced numbers of 
hepatic and splenic marginal macrophages (Cecchini et 
al., 1994) implicating these CSF-l-dependent mononu- 
clear phagocytes in the AIHA mediated by erythrophago- 
cytosis of antibody-coated RBCs through FcyRIII. 
Experimental Immune Thrombocytopenia in y-l- 
and oplop Mice 
Similar results were obtained in another model of type II 
hypersensitivity, experimentally induced immune throm- 
bocytopenia. The capacity of knockout mice to develop 
thrombocytopenia after challenge with MAb 6A6 (Mizutani 
et al., 1993) an IgGl specific for mouse platelets, was 
dramatically different from their wild-type littermates (Fig- 
ure 4). Wild-type animals demonstrated a rapid induction 
of thrombocytopenia following antibody challenge and de- 
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+/+ RaMRBC -/- RaMRBC 
Figure 2. Histological Aappearance of the Liver and Spleen in Wild-Type (u*) and Homozygous y Chain-Deficient Littermates (y*-) Injected with 
Rabbit aMRBC IgG or MAb 34-3C 
Liver and spleen are shown in (A) and (B), respectively. 
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Table 1. Hemolytic Anemia and Thrombocytopenia in Wild-Type, 
FcR Knockout, and Osteopetrotic Mice 
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Figure 3. Experimental Murine Immune Hemolytic Anemia Induced 
by Pathogenic Anti-Mouse RBC antibodies in Wild-Type and Homozy- 
gous y Chain-Deficient Littermates 
(A and B) Daily hematocrits of wild-type (+I+, closed squares) and 
homozygous y chain-deficient littermates (-I-, open squares) are 
shown for mice injected with MAb 34-X (A) and 31-9D (B). 
(C) Nadir hematocrits achieved by mice injected with pathogenic 
mouse aMRBC MAbs and rabbit aMRBC IgG. Mean hematocrits ob- 
tained from five mice in each group is presented. Hatched areas indi- 
cate the differences in anemia induction attributable to cobra venom 
factor treatment (CVF). 
veloped platelet counts 18% of baseline levels within 2 
hr postinjection. FcR-deficient mice are resistant to the 
pathogenic effects of this antibody, retaining platelet counts 
86% of baseline levels. Prior administration of an FcyRll 
and FcyRlll blocking antibody, 2.4G2 (Unkeless, 1979), 
Antibody Wild type ?-lb op/op 
a-MRBC 34-S 23% 46% 34% 
a-platelet 6A6 16% 66% 16% 
Data presented as mean absolute hematccrtt values or as percent of 
baseline platelet counts from five animals in each group. Mice (2-4 
months old) were used with antibody doses adjusted to body weight. 
resulted in a partial protection from GAG-induced thrombo- 
cytopenia, with platelet counts reaching 46% of baseline 
levels. These results are consistent with several clinical 
studies in which ITP has been treated with inhibitors of 
FcyRssuchas intravenousyglobulin, invivoimmunecom- 
plexes generated by anti-hRBC IgG, Fc fragments, and 
antibodies against F~Rlll, with varying degrees of suc- 
cess(Soubrane et al., 1993; Debre et al., 1993; Blanchette 
et al., 1994; Clarkson et al., 1986; Salama et al., 1983). 
In contrast with the situation with experimental AIHA, im- 
mune thrombocytopenia is identical in wild-type and oplop 
mice (Table l), indicating that different FcrR-expressing 
cells are responsible for the pathology of these two exam- 
ples of type II inflammation. 
Concluding Remarks 
These studies argue for a dominant role for Fc receptor 
engagement at an early step in the cascade of inflamma- 
tion initiated by cytotoxicantibodies in thetype II hypersen- 
sitivity class of inflammation. Despite the ability of these 
antibodies to fix complement and mediate target cell lysis 
in vitro, the situation in vivo appears to be quite different. 
As was found for immune complex-initiated inflammation 
(Sylvestre and Ravetch, 1994), Fc receptor engagement 
is also an early and critical step in the cascade of type II 
inflammation, supported by these data and in vitro studies 
on defects in y-l- mice in antibody-dependent cellular cyto- 
toxicity and phagocytosis in natural killer cells and mono- 
nuclear phagocytes (Takai et al., 1994; data not shown). 
The activation of effector cells by antibody-coated RBCs 
has been thought to be mediated by the synergistic coop 
eration of FcyR and C3b receptors (Schreiber and Frank, 
Figure 4. Experimental Immune Murine Thrombocytopenia Is Medi- 
ated by Fc Receptors 
Platelet counts (x lol/ul) from y-‘- mice (open squares) and y+‘+ mice 
(closed squares) and y+‘+ mice treated with Fc blocking antibody 2.462 
(triangles) are shown. Mean data from groups of four mice are shown. 
zptoxic Antibodies Trigger Inflammation Via FcyR 
1972) on the splenic macrophage and hepatic Kuppfer 
ceil. Our data using a polyclonal RaMRBC IgG fraction 
shows that in a system capable of both complement- 
dependent and independent activation pathways, Fc-rR 
receptor loss rather than complement depletion prevents 
immune hemolysis and argues for a minimal contributory 
role for complement activation. Confirmatory studies in 
complement-deficient animals would further strengthen 
this argument. These data further suggest that the hepatic 
Kuppfer cell or splenic marginal macrophage, which are 
reduced in adult op/op mice, are dominant in clearance of 
IgG-opsonized RBCs by erythrophagocytosis. In contrast, 
this same cell population is not required for clearance of 
IgGcoated platelets. 
These studies are especially relevant to the treatment 
of ITP and AIHA in humans. The efficacy of intravenous 
y globulin in the treatment of ITP has been attributed to 
both Fc receptor blockade and anti-idiotypic suppression 
of the autoreactive B cell clone (Salama et al., 1993). How- 
ever, the observation that Fe-r fragments are as effective 
(Debre et al., 1993), as well as the comparable efficacy 
of anti-hRBC (anti-D) (Blanchette et al., 1994) suggests 
that Fey receptor blockade is of prime importance. In con- 
trast with ITP, the treatment of AIHA with intravenous y 
globulin has met with only limited success (Flores et al., 
1993). Our findings support the notion that Fey blockade 
represents a potentially important therapeutic pursuit in 
AIHA. Indeed, Fey receptor blockade may have significant 
therapeutic utility in these diseases and in other disease 
states in which the uncoupling of pathogenic cell-bound 
antibody and the effector response may prevent injury. 
ExPsrlmental Procedures 
Mice 
y+ and wild-type littermates were developed as described previously 
(Takai et al., 1994). op/op mice were a gift from Dr. J. W. Pollard. All 
mice were maintained in the Rockefeller Research Laboratory mouse 
colony. Mice (2-4 months old) were used for all experiments. 
Antlbodlss 
The IgG fraction of rabbit a-mouse RBC sera (Cappel) was obtained 
by protein A-G affinity chromatography (Pierce). Mouse IgG MAbs 
(34-3C. 31-9D, and 6A6) were purified from ammonium sulphate-pre- 
cipitated concentrated tissue culture supernatants followed by protein 
A-G affinity chromatography. 4C6. an IgM mouse MAb, was purified 
from ammonium sulphate-concentrated tissueculture supernatant u5 
ing Sephacryl 200 (Pharmacia) gel filtration chromatography. Purity 
of all antibody preparations was confirmed by polyacrylamide gel elec- 
trophoresis. 
Experimental Immune Hemolytlc Anemia 
Mice were injected intraperitoneally with 120 pg of 34-3C or 70 ug of 
31-9D or 200 pg of 4C6 or rabbit aMRBC IgG. Cobra venom factor- 
treated mice received 10 pg cobra venom factor (Calbiochem) intraper- 
itoneally 24 hr prior to and 46 hr after injection of rabbit aMRBC IgG. 
Hematocrits were determined with heparinized microhematocrit capil- 
lary tubes (Becton-Dickinson) and a hematocentrifuge (Baxter) using 
200 pl of blood obtained from the retroorbital plexus. Hematoxylin- and 
eosin-stained formalin-fixed sections were prepared from P-monthold 
mice sacrificed 2 days after intraperitoneal injection with either 200 
pg of rabbit aMRBC IgG or 120 trg of MAb 34-3C. 
Expsrimsntal Immune Thrombocytopsnla 
Mice (2-4 months old) were injected intravenously with 15 pg of purifed 
mouse MAb 6A6. Blood (200 pl) obtained from the retroorbital plexus 
was diluted in buffer containing ammonium oxalate (Unopette Kits, 
Becton-Dickinson). Platelets were counted using a hematocytometer 
under a phase-contrast microscope. Fc-blocked r+‘+ mice received a 
maximal inhibitory dose (Kurlander et al., 1964) of 6 pg of MAb 2.4G2 
(Pharmingen) per gram of body weight intravenously 1 hr prior to injec- 
tion of MAb 6A6. 
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